Literature DB >> 12007909

Screening for androgen deficiency in women: methodological and interpretive issues.

André T Guay1.   

Abstract

OBJECTIVE: To appreciate the problems in obtaining and interpreting androgen levels in women.
DESIGN: Review of the literature to compare various laboratories and methods of analysis of serum androgens. PATIENT(S): Normal control populations culled from the literature to compare with patients previously reported on by us; data from our laboratory quality control compared with data from the literature. RESULT(S): Investigators and laboratories disagree as to the best methods of measuring testosterone (T) levels in women. Measuring DHEAS levels is much less controversial. CONCLUSION(S): Serum T levels should be measured in the morning hours and during the middle third of the menstrual cycle in premenopausal women. DHEAS levels may be measured at any time. Androgens decrease with age, but age-related levels are not accurate because current control populations have never been screened for sexual dysfunction. Such control populations need to be obtained.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12007909     DOI: 10.1016/s0015-0282(02)02965-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry.

Authors:  Micol S Rothman; Nichole E Carlson; Mei Xu; Christina Wang; Ronald Swerdloff; Paul Lee; Victor H H Goh; E Chester Ridgway; Margaret E Wierman
Journal:  Steroids       Date:  2010-11-09       Impact factor: 2.668

2.  The effects of partner togetherness on salivary testosterone in women in long distance relationships.

Authors:  Lisa Dawn Hamilton; Cindy M Meston
Journal:  Horm Behav       Date:  2009-11-10       Impact factor: 3.587

3.  Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

Authors:  C Derzko; S Elliott; W Lam
Journal:  Curr Oncol       Date:  2007-12       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.